
Obsessive-Compulsive Disorder (OCD) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Description
Obsessive-Compulsive Disorder (OCD) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Summary
This reports provides a data-driven overview of the current and future competitive
GlobalData’s Obsessive-Compulsive Disorder (OCD) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.
Components of the report include -
Summary
This reports provides a data-driven overview of the current and future competitive
- There will be more than 96,921,887 diagnosed prevalent cases of OCD in 2023 in the 16 major markets.
- The marketed drugs space for OCD is made up of small molecules. Their modes of action are mainly gamma-aminobutyric acid type A receptor subunit agonists and sodium dependent serotonin transporter inhibitors.
- R&D activity in OCD is poor, with only two drug molecule in late-stage development.
- Non-commercial sponsors dominated the clinical trial development in OCD overall, with Iran, Austral
GlobalData’s Obsessive-Compulsive Disorder (OCD) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.
Components of the report include -
- Disease Landscape
- Disease Overview
- Epidemiology Overview
- Treatment Overview
- Marketed Products Assessment
- Breakdown by Mechanism of Action, Molecule Type, Route of Administration
- Product Profiles with Sales Forecast
- Pricing and Reimbursement Assessment
- Annual Therapy Cost
- Time to Pricing and Time to Reimbursement
- Pipeline Assessment
- Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
- Product Profiles with Sales Forecast
- Late-to-mid-stage Pipeline Drugs
- Phase Transition Success Rate and Likelihood of Approval
- Clinical Trials Assessment
- Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
- Enrolment Analytics, Site Analytics, Feasibility Analysis
- Deals Landscape
- Mergers, Acquisitions, and Strategic Alliances by Region
- Overview of Recent Deals
- Commercial Assessment
- Key Market Players
- Future Market Catalysts
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the OCD market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global OCD market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Table of Contents
68 Pages
- Key Findings
- Disease Overview
- Epidemiology Overview - Total Prevalent Cases of OCD in 2023 and 2028
- Treatment Guidelines
- Treatment Algorithm for OCD
- Marketed Drugs - Leading Marketed Drugs in OCD
- Marketed Drugs - Overview by Mechanism of Action
- Marketed Drugs - Overview by Route of Administration
- Marketed Drugs - Annual Therapy Cost
- Pipeline Drugs Overview - Phase III and Phase II Pipeline Drugs in OCD
- Pipeline Drugs - Overview by Development Stage
- Pipeline Drugs - Overview by Mechanism of Action
- Pipeline Drugs - Overview by Route of Administration
- Pipeline Drugs - Overview by Molecule Type
- Pipeline Drugs - Drug-Specific Phase Transition Success Rate and Likelihood of Approval in OCD
- Pipeline Drugs - Phase Transition Success Rate and Likelihood of Approval in Central Nervous System Disorders
- Clinical Trials in OCD - Historical Overview
- Clinical Trials in OCD - Overview by Phase
- Clinical Trials in OCD - Overview by Status
- Clinical Trials in OCD - Overview by Phase for Ongoing and Planned Trials
- Clinical Trials in OCD - Trials with a Virtual Component
- Clinical Trials in OCD - Geographic Overview
- Clinical Trials in OCD - Single-Country and Multinational Trials by Region
- Clinical Trials in OCD- Top 20 Sponsors with Breakdown by Phase
- Clinical Trials in OCD - Top 20 Sponsors with Breakdown by Status
- Clinical Trials in OCD - Overview by Endpoint Status
- Clinical Trials in OCD - Overview by Race and Ethnicity
- Clinical Trials in OCD - Enrollment Data
- Clinical Trials in OCD - Overview of Sites by Geography
- Clinical Trials in OCD - Top 10 Countries for Trial Sites
- Clinical Trials in OCD - Top 20 Sites Globally
- Clinical Trials - Feasibility Analysis: Geography Overview
- Clinical Trials - Feasibility Analysis: Benchmark Models for OCD
- Deals Landscape - Mergers, Acquisitions, and Strategic Alliances in OCD by Region
- Deals Landscape - Recent Mergers, Acquisitions, and Strategic Alliances in OCD
- Commercial Assessment - Key Market Players in OCD
- Future Market Catalysts - Upcoming Market Catalysts in OCD
- Methodology
- Methodology - Sales Forecasts
- Methodology - Pricing and Reimbursement
- Methodology - Phase Transition Success Rate and Likelihood of Approval Analysis
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.